Device Trial Radar · NCT03711019
Efficacy of Convulsive Therapies During Continuation
Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Oct 22, 2018
Primary completion
Oct 10, 2024
Study completion Oct 10, 2024
Sponsor
- Lead sponsor
- Centre for Addiction and Mental HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of British Columbia; Ontario Shores Centre for Mental Health Sciences; Brain Canada
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.
Conditions
- Depression
- Bipolar Depression
- Unipolar Depression
- Treatment Resistant Depression
Interventions
Magnetic Seizure Therapy (MST)Device
MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
RUL-UB ECTDevice
In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Bitemporal ECTDevice
Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in HRSD-24 Scores between MST and RUL-UB at 6 monthsTime frame: 6 months
- Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)Time frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
UBC Hospital, University of British Columbia (UBC)
Vancouver, British Columbia, Canada
Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Ontario Shores Centre for Mental Health Sciences
Whitby, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.